Enhancing the sensitization of neuroblastoma to radiotherapy by the construction of a dual-channel parallel free radicals nanoamplifier
Source abstract
Abstract
Radiation therapy (RT) has emerged as one of the most promising anti-tumor strategies for neuroblastoma. Nevertheless, the special tumor microenvironment (TME), including hypoxic and GSH-overexpressed TME, often greatly restricts the RT outcome. In this study, we demonstrated a dual-channel parallel radicals nanoamplifier (ATO@PAE-PEG-AS1411/Fe3+). The nanoamplifier was shaped into a bilayer shell-core structure, in which atovaquone-loaded poly (β-amino esters)-poly (ethylene glycol) (ATO@PAE-PEG) served as the core while Fe3+-absorbed AS1411 aptamer (AS1411/Fe3+) served as the shell. Taking advantage of the targeting ability of AS1411, ATO@PAE-PEG-AS1411/Fe3+ specifically accumulated in tumor cells, and then released ATO as well as Fe3+ in response to the acidic TME. The released ATO dramatically inhibited the mitochondrial respiration of tumor cells, thus sparing vast amounts of oxygen for the generation of free radicals during RT process, which was the first free radicals-amplifying pathway Meanwhile, the released Fe3+ could consume the tumor-overexpressed GSH through the redox reaction, thus effectively preserving the generated free radicals in RT process, which was the second free radicals-amplifying pathway. Taken together, our study demonstrates a dual-channel parallel free radicals-amplifying RT strategy, and it is expected this work will promote the clinical application prospects of RT treatment against neuroblastoma.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Neuroblastoma Research and Treatments · Cancer, Hypoxia, and Metabolism · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (35)
Show source-provided references
1. Neuroblastoma10.1038/nrdp.2016.78 ↗
2. Advancing therapy for neuroblastoma10.1038/s41571-022-00643-z ↗
3. Cancer statistics, 2021
4. Expression of immunomodulatory checkpoint molecules in drug-resistant neuroblastoma: an exploratory study10.3390/cancers14030751 ↗
5. Recent advances in neuroblastoma10.1056/NEJMra0804577 ↗
6. Immunotherapy approaches targeting neuroblastoma10.1097/MOP.0000000000000982 ↗
7. Opportunities and challenges of radiotherapy for treating cancer10.1038/nrclinonc.2015.120 ↗
8. Excellent local control from radiation therapy for high-risk neuroblastoma10.1016/j.ijrobp.2008.10.069 ↗
9. Impact of radiotherapy for high-risk neuroblastoma: a Children's Cancer Group study10.1016/S0360-3016(02)04506-6 ↗
10. Dose-escalation is needed for gross disease in high-risk neuroblastoma, Pediatr
11. Local control with 21-gy radiation therapy for high-risk neuroblastoma10.1016/j.ijrobp.2016.05.020 ↗
12. Long-term survival of neuroblastoma patients receiving surgery, chemotherapy, and radiotherapy: a propensity score matching study10.3390/jcm12030754 ↗
13. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery10.1200/JCO.2001.19.11.2821 ↗
14. Prospective evaluation of radiation dose escalation in patients with high-risk neuroblastoma and gross residual disease after surgery: a report from the children's oncology group ANBL0532 study10.1200/JCO.19.03316 ↗
15. Application of radiosensitizers in cancer radiotherapy10.2147/IJN.S290438 ↗
16. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 201810.1038/s41418-017-0012-4 ↗
17. State-of-the-art strategies for targeting the DNA damage response in cancer10.1038/s41571-018-0114-z ↗
18. Cancer radiosensitizers10.1016/j.tips.2017.11.003 ↗
19. Hypoxia in the initiation and progression of neuroblastoma tumours10.3390/ijms21010039 ↗
20. Engineering nanomedicine for glutathione depletion-augmented cancer therapy10.1039/D0CS00718H ↗
21. Covalent organic polymers based on fluorinated porphyrin as oxygen nanoshuttles for tumor hypoxia relief and enhanced photodynamic therapy10.1002/adfm.201804901 ↗
22. Catalase-functionalized iron oxide nanoparticles reverse hypoxia-induced chemotherapeutic resistance10.1002/adhm.201900826 ↗
23. Hyaluronidase embedded in nanocarrier PEG shell for enhanced tumor penetration and highly efficient antitumor efficacy10.1021/acs.nanolett.6b00820 ↗
24. Integration of immunogenic activation and immunosuppressive reversion using mitochondrial-respiration-inhibited platelet-mimicking nanoparticles10.1016/j.biomaterials.2019.119699 ↗
25. O2 economizer for inhibiting cell respiration to combat the hypoxia obstacle in tumor treatments
26. Overcoming hypoxia by multistage nanoparticle delivery system to inhibit mitochondrial respiration for photodynamic therapy
27. Study on chemical modifications of glutathione by cold atmospheric pressure plasma (cap) operated in air in the presence of Fe(II) and Fe(III) complexes10.1038/s41598-019-53538-y ↗
28. pH-sensitive micelles self-assembled from polymer brush (PAE-g-cholesterol)-b-PEG-b-(PAE-g-cholesterol) for anticancer drug delivery and controlled release10.2147/IJN.S130037 ↗
29. Progress in cancer drug delivery based on AS1411 oriented nanomaterials10.1186/s12951-022-01240-z ↗
30. Therapeutic applications of AS1411 aptamer, an update review10.1016/j.ijbiomac.2019.11.118 ↗
31. A DNA nanorobot functions as a cancer therapeutic in response to a molecular trigger in vivo10.1038/nbt.4071 ↗
32. On the in vivo photochemical rate parameters for PDT reactive oxygen species modeling10.1088/1361-6560/62/5/R1 ↗
33. Synergistic effect of well-defined dual sites boosting the oxygen reduction reaction10.1039/C8EE02656D ↗
34. Assay for quantitative determination of glutathione and glutathione disulfide levels using enzymatic recycling method10.1038/nprot.2006.378 ↗
35. Glutathione-responsive and -exhausting metal nanomedicines for robust synergistic cancer therapy